Document Detail


Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.
MedLine Citation:
PMID:  2095753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Whether patients in clinical remission for acute lymphoblastic leukemia (ALL) continue to harbor leukemic cells is not known, because methods of detecting residual malignant cells have not been sufficiently sensitive. This information might be useful for predicting recurrence and determining the duration of therapy. METHODS: Using a sensitive new method--identifying complementarity-determining region III sequences with the polymerase chain reaction--we estimated the number of residual leukemic cells in the bone marrow of eight children with B-lineage lymphoblastic leukemia before and after remission. RESULTS: Induction chemotherapy produced a 3-to-4-log reduction in the number of leukemic cells. In all samples obtained up to 18 months after diagnosis, however, 0.004 to 2.6 percent of bone marrow nucleated cells were residual leukemic cells. Among the four patients studied more than 18 months after diagnosis, three had no detectable leukemic cells in marrow samples. Despite this, one of them, who was no longer receiving therapy, had a central nervous system relapse. In one patient receiving maintenance chemotherapy, there was a 60-fold increase in leukemic cells three months before bone marrow relapse. CONCLUSIONS: The complete disappearance of leukemic cells (or their reduction below our method's threshold of detection, 1 in 100,000 cells) may be necessary to achieve a cure of ALL. The quantification of residual leukemic cells in serial marrow aspirates during therapy may allow the early detection of relapse.
Authors:
M Yamada; R Wasserman; B Lange; B A Reichard; R B Womer; G Rovera
Related Documents :
2006173 - Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory...
9108413 - Expression of the ret receptor tyrosine kinase and gdnfr-alpha in normal and leukemic h...
4059803 - Mast cells on the surface of the mucous membrane--a general feature of inflammatory rea...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The New England journal of medicine     Volume:  323     ISSN:  0028-4793     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  1990 Aug 
Date Detail:
Created Date:  1990-08-30     Completed Date:  1990-08-30     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  448-55     Citation Subset:  AIM; IM    
Affiliation:
Wistar Institute, Philadelphia, PA 19104.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Base Sequence
Bone Marrow / pathology*
Burkitt Lymphoma / drug therapy,  pathology*
Child
Child, Preschool
DNA, Neoplasm / analysis
Female
Humans
Infant
Male
Molecular Sequence Data
Polymerase Chain Reaction
Time Factors
Grant Support
ID/Acronym/Agency:
CA 10819/CA/NCI NIH HHS; CA 47983/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/DNA, Neoplasm
Comments/Corrections
Comment In:
N Engl J Med. 1991 Mar 14;324(11):772-5   [PMID:  1997845 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Severe hemolysis after incomplete mitral valve repair.
Next Document:  Earlobe crease and atherosclerosis. An autopsy study.